TEVA PHARMACEUTICAL INDUSTRIES LTD 4

Placid Jover (EVP & CHRO of Teva) had 12,827 RSUs vest into ordinary shares and then sold all 12,827 shares for about $447K while retaining 6,774 shares and 25,657 RSUs.

On August 3, 2026, Placid Jover, Executive Vice President and Chief Human Resources Officer of Teva Pharmaceutical Industries Ltd., had 12,827 restricted share units vest and convert into an equivalent number of ordinary shares at a deemed price of $0 (an RSU-to-share conversion), and then sold all 12,827 resulting ordinary shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan at a weighted-average price of approximately $34.88 per share, for proceeds of about $447,400, largely to cover tax obligations associated with the vesting. Following these transactions, he reported direct ownership of 6,774 ordinary shares and 25,657 remaining restricted share units, whose combined value is approximately $1.12 million based on the current share price. The RSUs stem from an August 1, 2024 grant that vests in annual tranches from 2025 through 2028, and the ordinary shares may be represented by American Depositary Shares on a one-for-one basis.

Filing Facts

CIK

818686

Ticker

TEVA

Form

4

Source Type

fda

Accession

0001193125-26-335026

Alert Tier

5